UPDATE ON DELAWARE HEALTH

NOVEMBER 9, 2020

Karyl T. Rattay, MD, MS, Director
Division of Public Health
Delaware Department of Health and Social Services
COVID-19 AND HEALTH CARE PROVISION

• Increases in patients seeking care for respiratory illness that could be COVID-19.
• Deferring and delaying non-COVID-19 care
• Disruptions in supply chains
• Fluctuations in facilities’ occupancy
• Absenteeism among staff because of illness or caregiving responsibilities
• Increases in mental health concerns.
4 in 10 U.S. adults reported avoiding medical care because of concerns related to COVID-19*

Delaying or avoiding urgent or emergency care was more common among:

- People with disabilities
- People with two or more underlying conditions

Telehealth may help people get the care they need

Even during the COVID-19 pandemic, people who experience a medical emergency should seek care without delay

*CDC.gov/MMWR91020
Impressive reductions in common childhood infectious diseases
Pediatric immunizations

STD

HIV

Campylobacteriosis

Hepatitis B

Lyme Disease

Today’s focus
PEDIATRIC IMMUNIZATION TRENDS
Delaware, September 2018-September 2020

DtaP Vaccine Administered

Polio Vaccine Administered

Source: Delaware Immunization System, 2020
PEDIATRIC IMMUNIZATION TRENDS
Delaware, September 2018-September 2020

MMR Vaccine Administered

HIB Vaccine Administered

Source: Delaware Immunization System, 2020
PEDiatric IMMUNIZATION TRENDS
Delaware, September 2018-September 2020

Source: Delaware Immunization System, 2020
## HIV HARM REDUCTION SERVICES

<table>
<thead>
<tr>
<th>Service</th>
<th>Jan – Mar</th>
<th>Apr – Jun</th>
<th>Jul – Sep</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid HIV Tests Performed</td>
<td>2,072</td>
<td>508</td>
<td>751</td>
</tr>
<tr>
<td>Syringes Exchanged</td>
<td>55,666</td>
<td>59,059</td>
<td>58,779</td>
</tr>
<tr>
<td>Clients Referred to a PrEP Provider</td>
<td>297</td>
<td>76</td>
<td>123</td>
</tr>
<tr>
<td>Condoms mailed to Participants</td>
<td>750</td>
<td>744</td>
<td>745</td>
</tr>
<tr>
<td>Percent of new HIV clients interviewed by DIS w/in 30 days</td>
<td>80%</td>
<td>100%</td>
<td>50%</td>
</tr>
<tr>
<td>Percent of new HIV patients linked to care w/in 30 days</td>
<td>100%</td>
<td>100%</td>
<td>50%</td>
</tr>
</tbody>
</table>

Source: Delaware SSP data
HIV Cases by Sex at Birth, Delaware, first three quarters, 2020

Source: Enhanced HIV/AIDS Reporting System (eHARS)
Men Who have Sex with Men (MSM)
Intraveous Drug Use (IDU)
MSM and also IDU
Heterosexual Contact
Unknown or Not Reported

HIV Cases by Exposure Risk, Delaware, first three quarters, 2020

Source: Enhanced HIV/AIDS Reporting System (eHARS)
<table>
<thead>
<tr>
<th>Gender</th>
<th># of Clients</th>
<th>% of Clients</th>
<th># of Clients</th>
<th>% of Clients</th>
<th># of Clients</th>
<th>% of Clients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st QTR</td>
<td>1st QTR</td>
<td>2nd QTR</td>
<td>2nd QTR</td>
<td>3rd QTR</td>
<td>3rd QTR</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>742</td>
<td>68.80%</td>
<td>504</td>
<td>68.40%</td>
<td>454</td>
<td>67%</td>
</tr>
<tr>
<td>Female</td>
<td>329</td>
<td>30.60%</td>
<td>230</td>
<td>31.20%</td>
<td>218</td>
<td>32%</td>
</tr>
<tr>
<td>Transgender</td>
<td>7</td>
<td>0.6</td>
<td>3</td>
<td>0.40%</td>
<td>3</td>
<td>0.4%</td>
</tr>
</tbody>
</table>

Source: Ramsell pharmacy benefits system
Campylobacteriosis Cases, Delaware, January through September, 2019 and 2020

Source: DERRS data
Lyme Disease Cases, Delaware, January through September, 2019 and 2020

Source: DERRS data
Hepatitis B Cases, Delaware, January through September, 2019 and 2020

Source: DERRS data
### 2020-2021 Flu Vaccine Choices

<table>
<thead>
<tr>
<th>FLU VACCINE</th>
<th>AGE RANGE</th>
<th>TYPE</th>
<th>PRODUCTION</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFLURIA QUADRIVALENT*</td>
<td>6 months and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Seqirus</td>
</tr>
<tr>
<td>FLUAD QUADRIVALENT (adjuvanted)</td>
<td>65 and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Seqirus</td>
</tr>
<tr>
<td>FLUAD TRIVALENT (adjuvanted)</td>
<td>65 and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Seqirus</td>
</tr>
<tr>
<td>FLUARIX QUADRIVALENT*</td>
<td>6 months and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Glaxo</td>
</tr>
<tr>
<td>FLUBLOK QUADRIVALENT</td>
<td>18 and up</td>
<td>shot</td>
<td>genetic recombining process</td>
<td>Sanofi</td>
</tr>
<tr>
<td>FLUCELVAX QUADRIVALENT*</td>
<td>4 and up</td>
<td>shot</td>
<td>cell-based</td>
<td>Seqirus</td>
</tr>
<tr>
<td>FLULAVAL QUADRIVALENT*</td>
<td>6 months and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Glaxo</td>
</tr>
<tr>
<td>FLUMIST QUADRIVALENT</td>
<td>2 and 49</td>
<td>nasal spray</td>
<td>egg-based with live weakened vaccine</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>FLUZONE QUADRIVALENT (High Dose)</td>
<td>65 and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Sanofi</td>
</tr>
<tr>
<td>FLUZONE QUADRIVALENT*</td>
<td>6 months and up</td>
<td>shot</td>
<td>egg-based</td>
<td>Sanofi</td>
</tr>
</tbody>
</table>

* Doses obtained from vials contain preservatives; prefilled syringes do not

chart by AskaPatient.com, July 2020 from CDC, FDA Vaccine and DailyMed database
A new FDA–approved multiplex diagnostic assay for detection of both COVID-19 and influenza viruses could improve future surveillance efforts. 

Source: CDC, MMWR, September 18, 2020, Vol. 69, No. 37
Coping with COVID-19

- Take breaks from the news
- Take care of your body
- Make time to unwind
- Connect with others
- Set goals and priorities
- Focus on the facts
Keep up the great work!
THANK YOU FOR ATTENDING

Delaware COVID-19 website
de.gov/coronavirus

Delaware Health Alert Network online registration system
healthalertde.org/

Karyl T. Rattay, MD, MS, FAAP
Director, Division of Public Health
Karyl.Rattay@Delaware.gov
302-744-4701